Investing Ideas
/
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.

2 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	2268 WuXi XDC Cayman	HK$32.00	2.6%	-4.2%	HK$38.3b	HK$32.07	PE60.5x	E27.5%	n/a
	1548 Genscript Biotech	HK$9.74	-3.6%	-49.1%	HK$20.9b	HK$22.68	PS2.7x	E112.9%	0%

Page 1 of 1